TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3783203
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy with CMFp + T
Study: 3783203
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone with p + T
Study: 3783203
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy (CMFp + T) and observation
Study: 27925651
Drug: 40 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg/d LNG
Study: 27925651
Drug: 300, 600,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300, 600, or 1050 μg/d ATZ combined with 40 μg/d LNG
Study: 27925651
Drug: ATZ in
Normalized name: ATZ
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ATZ in the dose range investigated
Study: 24630348
Drug: Intramuscular botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular botulinum toxin A (BoNT‐A) injections (n = 23)
Study: 17982194
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment with vitamin D(3), VK(2), and EHDP
Study: 7733075
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. x 8 days, Clarithromycin 500 mg b.i.d., CBS 120 mg q.i.d. for 7 days
Study: 7733075
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. x 8 days, Clarithromycin 500 mg b.i.d. (without CBS)
Study: 2282998
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg t.i.d. and 400 mg nocte for 6 weeks
Study: 2282998
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg b.i.d. for 6 weeks
Study: 28391418
Drug: Amoxicillin-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-containing quadruple therapy (esomeprazole 20 mg twice/day, amoxicillin 1000 mg twice/day, levofloxacin 500 mg once/day, bismuth 220 mg twice/day for 14 days)
Study: 28391418
Drug: Cefuroxime-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime-containing quadruple therapy (esomeprazole 20 mg twice/day, cefuroxime 500 mg twice/day, levofloxacin 500 mg once/day, bismuth 220 mg twice/day for 14 days)
Study: 17426677
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of simvastatin and aspirin
Study: 12759560
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg brotizolam (BRZ)
Study: 11040171
Drug: Topical amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amethocaine gel (1.5 g applied to the dorsum of either foot)
Study: 11040171
Drug: Placebo (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.5 g applied to the dorsum of either foot)
Study: 1428312
Drug: Diclofenac (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (3 x 50 mg for 6 weeks)
Study: 3553279
Drug: L-649,923
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-649,923
Study: 27721995
Drug: Sensory Enrichment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory Enrichment Therapy
Study: 20016012
Drug: High-energy-density (HED)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy-density (HED) snack food (60g daily for 14 days)
Study: 20016012
Drug: Low-energy-density (LED)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy-density (LED) snack food (60g daily for 14 days)
Study: 18089623
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of sulodexide
Study: 18089623
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of sulodexide
Study: 17108871
Drug: Various medical
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various medical strategies for weight loss (dietary intervention, physical activity, behavior modification, pharmacotherapy, surgery)
Study: 14604717
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral clorazepate dipotassium
Study: 14604717
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intravenous midazolam
Study: 8810584
Drug: Large stimulus
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large stimulus (L)
Study: 1430679
Drug: Combination thrombolytic
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination thrombolytic therapy (rt-PA and urokinase)
Study: 1430679
Drug: Urokinase monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase monotherapy
Study: 1430679
Drug: rt-PA monotherapy
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA monotherapy
Study: 6374780
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg daily for five days a week)
Study: 30187524
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose (D5W) injection, 5ml
Study: 30187524
Drug: Corticosteroid (triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (triamcinolone acetonide) injection, 3ml mixed with 2ml normal saline
Study: 17972359
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg/day plus selegiline 10 mg/day (5 mg bid)
Study: 12955641
Drug: Single-dose liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose liposomal amphotericin B (L-AmB) 7.5 mg/kg
Study: 10735688
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of mannitol, furosemide, and dopamine (group B)
Study: 10735688
Drug: Intermittent doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent doses of diuretics (furosemide, bumetadine, and ethracrynic acid) and fluids (group A)
Study: 8716750
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of morphine (CIM)
Study: 8716750
Drug: Intermittent intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intramuscular injection of pethidine (IMP)
Study: 4006549
Drug: Short-term intravenous
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intravenous naloxone administration
Study: 30702403
Drug: Bleaching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching treatment with room temperature storage (21.04°C±3.13°C)
Study: 30702403
Drug: Bleaching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching treatment with refrigerated storage (5°C)
Study: 30702403
Drug: Consistency test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistency test of bleaching gels
Study: 28034564
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml black tea
Study: 24065124
Drug: PEG‐IFN/RBV combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN/RBV combination therapy
Study: 12552319
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose solutions (Group 2)
Study: 10601539
Drug: Ornithine alpha-ketoglutarate
Normalized name: ornithine alpha-ketoglutarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornithine alpha-ketoglutarate (20 g/day)
Study: 24083027
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (twice a week for eight weeks)
Study: 9037323
Drug: Phenylephrine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (1 microgram/kg) infusion
Study: 9037323
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (1 microgram/kg) infusion
Study: 8584604
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion (5% sodium chloride at 0.06 ml/kg/min)
Study: 8584604
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (0.9% sodium chloride at 0.06 ml/kg/min)
Study: 2670535
Drug: ACC‐9653 (PHT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC‐9653 (PHT prodrug) administered intravenously (i.v.)
Study: 2670535
Drug: ACC‐9653 (PHT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC‐9653 (PHT prodrug) administered intramuscularly (i.m.)
Study: 25814428
Drug: Six different
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six different moistening solutions (specific solutions not detailed)
Study: 24372155
Drug: Fast ice
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast ice cream consumption (5 min)
Study: 24372155
Drug: Slow ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow ice cream consumption (30 min)
Study: 19221352
Drug: Rapid-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-acting insulin analogues (insulin lispro)
Study: 19221352
Drug: Rapid-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-acting insulin analogues (insulin aspart)
Study: 19221352
Drug: Rapid-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-acting insulin analogues (insulin lispro) in type 2 diabetes
Study: 19221352
Drug: Rapid-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-acting insulin analogues (insulin aspart) in type 2 diabetes
Study: 19221352
Drug: Long-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting insulin analogues (insulin glargine)
Study: 19221352
Drug: Long-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting insulin analogues (insulin detemir)
Study: 19221352
Drug: Long-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting insulin analogues (insulin glargine) in type 2 diabetes
Study: 19221352
Drug: Long-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting insulin analogues (insulin detemir) in type 2 diabetes
Study: 15378838
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of plutonium
Study: 15378838
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of gamma rays
Study: 12600112
Drug: Aprotinin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (3 x 10^6 added to the priming solution of ECC)
Study: 12600112
Drug: Amrinone combined
Normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amrinone combined with aprotinin (3 x 10^6 aprotinin + bolus of 1 mg/kg amrinone followed by 8 micrograms/(kg.min) maintenance infusion)
Study: 3099486
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 5 mg (30 mg/day)
Study: 3099486
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 20 mg (120 mg/day)
Study: 3099486
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 40 mg (240 mg/day)
Study: 3099486
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 80 mg (480 mg/day)
Study: 3099486
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of ISDN 80 mg (480 mg/day) for 4 weeks
Study: 3099486
Drug: Nitroglycerin 2.6
Normalized name: nitroglycerin 2.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin 2.6 mg (single dose)
Study: 3099486
Drug: Nitroglycerin 6.5
Normalized name: nitroglycerin 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin 6.5 mg
Study: 3099486
Drug: Nitroglycerin 10
Normalized name: nitroglycerin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin 10 mg
Study: 3099486
Drug: Nitroglycerin 20
Normalized name: Nitroglycerin 20 mg/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin 20 mg
Study: 3099486
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin 5 cm2 patch
Study: 3099486
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin 10 cm2 patch
Study: 3099486
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin 20 cm2 patch
Study: 29458406
Drug: Pyriproxyfen/spinosad combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyriproxyfen/spinosad combination treatment of permanent water storage containers
Study: 19879596
Drug: Colesevelam 1.875
Normalized name: colesevelam 1.875 g oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 1.875 g/d
Study: 16839823
Drug: contact‐control delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: contact‐control delayed treatment group
Study: 8534533
Drug: 3 L
Normalized name: D3 Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 L of balanced electrolyte/polyethylene glycol solution (PEG)
Study: 8534533
Drug: Senna laxatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna laxatives and sodium phosphate enemas
Study: 7004480
Drug: Chymoral (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chymoral (exact dosage and duration not specified)
Study: 31908066
Drug: SR-dexamphetamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR-dexamphetamine (2 x 30 mg/day)
Study: 30422953
Drug: Immunosuppressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressant therapy
Study: 29211123
Drug: Morse Taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morse Taper (MT) implants
Study: 24936090
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment consisting of a leaflet on health and lifestyle
Study: 14756387
Drug: Regitine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regitine 40 mg tablet formulation
Study: 14756387
Drug: Vasomax 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasomax 40 mg tablet formulation
Study: 9776327
Drug: Antiepileptic drug
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drug treatment (AEDs)
Study: 9776327
Drug: Post-drug discontinuation
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-drug discontinuation assessment
Study: 3053457
Drug: Prophylactic systemic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic systemic antibiotics (PSA) in a conventional hospital room (PSA group, 101 patients)
Study: 31702883
Drug: Difelikefalin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difelikefalin (0.5 μg/kg)
Study: 27397551
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy without antifungal prophylaxis
Study: 25938241
Drug: Guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-based cognitive-behavioral therapy (iCBT) for 9 weeks
Study: 20089204
Drug: B-vitamin supplements
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin supplements (folate 1 mg, vitamin B12 500 microg, vitamin B6 10 mg)
Study: 19127918
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of tablet Caltrate with Vit D2
Study: 16859470
Drug: Intrarectal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal and anal EMLA cream (subgroup A)
Study: 16859470
Drug: Ultrasound gel
Normalized name: Ultrasound gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound gel as placebo (subgroup B)
Study: 14516238
Drug: Internet-driven treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-driven treatment of posttraumatic stress
Study: 1633720
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg hidrosmin, 1 capsule 3-times daily for 45 days
Study: 1633720
Drug: Placebo, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 capsule 3-times daily for 45 days
Study: 31372762
Drug: Metabolomic profiling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolomic profiling in patients with myasthenia gravis (MG)
Study: 27473188
Drug: Ultra-micronized palmitoylethanolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-micronized palmitoylethanolamide (um-PEA) 600 mg twice a day
Study: 23512705
Drug: IBHB (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBHB (300 mg, twice daily)
Study: 20637968
Drug: Crushed pellets
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed pellets from MS-sNT (60 mg morphine/2.4 mg naltrexone)
Study: 20637968
Drug: Naltrexone solution
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone solution (2.4 mg)
Study: 20637968
Drug: Whole MS-sNT
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole MS-sNT capsule (60 mg morphine/2.4 mg naltrexone)
Study: 20637968
Drug: Naltrexone solution
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone solution
Study: 17252564
Drug: Chemotherapy intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy intensification (Capizzi II)
Study: 7325345
Drug: Fentanyl epidurally
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl epidurally (0.1‐0.2 mg diluted with 0.9% saline solution)
Study: 7325345
Drug: Systemic opiate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic opiate therapy by intramuscular application of piritramide (Dipidolor, 15‐25 mg)
Study: 23514242
Drug: Real Time
Normalized name: MENTHOL 15 mg in 1 g TOPICAL CREAM [Real Time Pain Relief Foot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real Time Medication Monitoring system (RTMM) with tailored text-messages
Study: 21291439
Drug: Parents in
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents in treatment for depression
Study: 16430412
Drug: Caudal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ketamine (0.25 mg.kg(‐1)) plus lidocaine (2%, 2 mg.kg(‐1))
Study: 16430412
Drug: Caudal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ketamine (0.25 mg.kg(‐1)) plus tramadol (1 mg.kg(‐1))
Study: 12830445
Drug: Short daily
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short daily hemodialysis (n = 11)
Study: 12830445
Drug: Conventional thrice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional thrice-weekly hemodialysis (n = 22)
Study: 9337184
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 U bolus followed by 1000 to 1200 U/h)
Study: 9337184
Drug: Low-dose hirulog
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hirulog (0.125 mg/kg bolus followed by 0.25 mg x kg(‐1) x h(‐1) for 12 hours then 0.125 mg x kg(‐1) x h(‐1))
Study: 9337184
Drug: High-dose hirulog
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hirulog (0.25 mg/kg bolus followed by 0.5 mg x kg(‐1) x h(‐1) for 12 hours then 0.25 mg x kg(‐1) x h(‐1))
Study: 9337184
Drug: Low-dose hirulog
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hirulog
Study: 9337184
Drug: High-dose hirulog
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hirulog
Study: 30374692
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg IV CRH
Study: 24378745
Drug: d‐amphetamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine (0.3 mg/kg, p.o.)
Study: 15122555
Drug: Viewing a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viewing a treatment simulation before surgery
Study: 15122555
Drug: Standard presurgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard presurgical consultation without treatment simulation
Study: 11476123
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg for first two injections; 5 mg for third injection)
Study: 11476123
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg for first two injections; 1 mg for third injection)
Study: 11476123
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo for first two injections; olanzapine 10 mg for third injection)
Study: 7840527
Drug: CAV-E (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV-E (cyclophosphamide 1000 mg/m2, adriamycin 50 mg/m2, vincristine 2 mg, plus etoposide 100 mg/m2)
Study: 7840527
Drug: CAV-T (teniposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV-T (teniposide 60 mg/m2 on days 2, 3, 4)
Study: 7840527
Drug: alpha-interferon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-interferon (3 x 10(6) I.U., i.m. daily x 9 months)
Study: 3295323
Drug: Cefixime (CFIX)
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime (CFIX) 100 mg b.i.d.
Study: 3295323
Drug: Cefroxadine (CXD)
Normalized name: cefradine
DrugBank: Cefroxadine (DB11367)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefroxadine (CXD) 250 mg t.i.d.